Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system

OBJECTIVE: To evaluate the long-term cost-effectiveness of different strategies for human papillomavirus (HPV) DNA testing combined with Pap smear for cervical cancer screening in Taiwan.

METHODS: This study adopts a perspective of Department of Health in cost-effectiveness analysis to compare a no-screening strategy with nine different screening strategies. These strategies comprise three screening tools (Pap smear alone, HPV DNA testing followed by Pap smear triage, and HPV DNA testing combined with Pap smear), and three screening intervals (annually, every 3 years, and every 5 years). Outcomes are life expectancy, quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs). Probabilistic sensitivity analyses (PSAs) were conducted to assess parameter uncertainty.

RESULTS: When three times gross domestic product per capita is used as the decision threshold, all nine screening strategies were cost-effective compared with the no-screening strategy. Compared with the current screening strategy (an annual Pap smear), HPV DNA testing followed by Pap smear triage every 5 years and every 3 years were cost-effective. Results of PSA also indicated that a HPV DNA testing followed by Pap smear triage every 5 or every 3 years achieved the highest expected net benefits.

CONCLUSIONS: Possible economic advantages are associated with extending the cervical cancer screening interval from one Pap smear screening to HPV DNA testing followed by Pap smear triage every 5 or every 3 years achieved the highest expected net benefits. Results of PSA also indicated that a HPV DNA testing followed by Pap smear triage every 5 years and every 3 years were cost-effective. Compared with the current screening strategy (an annual Pap smear), HPV DNA testing followed by Pap smear triage every 5 years and every 3 years were cost-effective. Results of PSA also indicated that a HPV DNA testing followed by Pap smear triage every 5 or every 3 years achieved the highest expected net benefits. 

Keywords: HPV DNA testing; Pap smear; cost-effectiveness analysis; cervical cancer; screening

Cervical cancer is one of the most common cancers in Taiwan, currently ranked as the fifth leading cancer causing death for females (Chen et al., 2009). Although the incidence and mortality associated with cervical cancer have declined steadily since the National Health Insurance (NHI) program was instituted in 1995, the incidence of cervical cancer in Taiwan is still one of the highest in Asia and is a huge burden to the health-care system.

All females in Taiwan aged ≥ 30 years are now provided with a free Pap smear annually by the NHI system (Koong et al., 2006). The annual Pap smear screening rate for females aged 30–69 years increased to 27.4% in 2007 from 14.3% in 1996. The 3-year coverage rate reached 52.4% during 2005–2007; 5-year coverage was roughly 60% during 2003–2007 (Bureau of Health Promotion, 2007). In France, 60% of the female population had a regular Pap smear within the last 3 years (Schaffer et al., 2000), 80% of Dutch females and 85% of English females had a Pap smear within the last 5 years (Patnick, 2000; Van Ballegooijen and Hermens, 2000). Notably, the screening program in Taiwan has not yet achieved satisfactory coverage. The health authorities in Taiwan currently face the challenge of implementing cervical cancer screening programs with increased effectiveness.

A population-based randomised trial conducted in Sweden indicated that primary the human papillomavirus (HPV) DNA testing with Pap smear triage and repeat HPV DNA testing for those who test positive in HPV DNA testing with negative Pap smear results were the most effective cervical cancer screening strategy (Naucler et al., 2009). Recent findings from a cohort study on long-term outcomes of HPV infection in Taiwan demonstrated that, for a female who had a normal Pap smear result, the 6-year cumulative risk of developing high-grade squamous intraepithelial lesions (HSILs) was 10.0% when the HPV DNA testing result was positive, whereas the risk for those with negative HPV DNA testing was only 0.34%. These data support the efficacy of HPV DNA testing for cervical cancer screening program with intervals of at least 5 years (Huang et al., 2008). Another European study of six
countries also suggested that screening intervals could safely be lengthened to 6 years among females with a negative HPV DNA testing result (Dillner et al., 2008).

In two systematic review studies, Holmes et al. (2005) and Muhlberger et al. (2008) summarised existing evidence for the cost-effectiveness of incorporating the HPV DNA testing into current cervical cancer screening programs. Their analytical results showed the HPV DNA testing with a Pap smear as a screening strategy for females aged $\geq 30$ years was cost-effective. With an incremental cost-effectiveness ratio (ICER) threshold of NT$1 620 000 per quality-adjusted life year (QALY), Muhlberger et al. (2008) concluded that, in comparison with annual Pap smear, or Pap smear every 2, 3, or 5 years, the probabilities of HPV DNA testing strategies being cost-effective were 83, 25, 55, and 92%, respectively. These analytical findings illustrate that when evaluating the cost-effectiveness of the HPV DNA testing, the screening interval should be considered.

Several studies utilised computer-based models to estimate the cost-effectiveness of adding the HPV DNA testing to current cervical cancer screening programs in Sweden, Canada, the United States, the United Kingdom, the Netherlands, France, Italy, and Germany. Adding the HPV DNA testing can reduce cancer incidence and is less costly than Pap smear alone (Mandelblatt et al., 2002b; Mittendorf et al., 2003; Goldie et al., 2004; Kim et al., 2005; Bistoletti et al., 2008; Chuck, 2009).

In Taiwan, which has a poor Pap smear participation rate, policy makers face the problems of whether to combine the HPV DNA testing with Pap smear for cervical cancer screening and determining the optimal screening interval. This study evaluates the long-term cost-effectiveness of different strategies for HPV DNA testing combined with Pap smear for cervical cancer screening in Taiwan for healthy females aged 30 years.

MATERIALS AND METHODS

Cost-effectiveness analysis and decision analytic model

This cost-effectiveness analysis (CEA) adopts the perspective of Department of Health. A decision analytic model was developed using TreeAge Pro Suite 2009 software (TreeAge Software, Inc., Williamstown, MA, USA) for evaluating the long-term costs and effectiveness of various cervical cancer screening strategies. This study used clinical outcome measures, including cervical cancer incidence, mortality, life expectancy, and QALYs. All costs, life expectancy, and QALYs were discounted to their present values at an annual rate of 3%. The ICERs were calculated as the difference in cost divided by the difference in QALYs for each strategy compared with the no-screening strategy, with the strategy of an annual Pap smear, or with the next-best strategy. Currently, no consensus exists for a specific cost-effectiveness threshold in Taiwan. However, this study considered strategies with ICER values less than three times per capita gross domestic product (GDP) as cost-effective (Eichler et al., 2004). In 2008, Taiwan’s per capita GDP was NT$538 790 (Directorate-General of Budget, Accounting and Statistics, 2009a). Therefore, the cost-effectiveness threshold assumed in this model was NT$1 620 000/QALY.

Natural history model

The natural history model for cervical cancer was adopted from literature (Debicki et al., 2008; Rogoza et al., 2008; Suárez et al., 2008). The health states of the decision analytic model for the natural history of cervical cancer among females have the following seven categories: normal (healthy); HPV infection; grades of cervical intraepithelial neoplasia (CIN) (CIN I, CIN II or III); persistent CIN II or III; stage of cervical cancer; death from other causes; and, death from cervical cancer. This model simulates a cohort of 30-year-old healthy females; the hypothetical cohort moves between different health states according to prespecified probabilities in each Markov cycle (1 year). The analytical time horizon was lifetime (85 years old).

The model starts with a cohort of 30-year-old healthy females (normal state). During simulation, individuals may remain in the normal state or progress to the HPV infection state in the next year (or cycle). Individuals with HPV infection may remain in the HPV infection state, regress to the normal state, or progress towards the CIN I state. The CIN I patients may remain in the CIN I state, regress to the normal state, or progress towards the CIN II or III state. The CIN II or III patients may remain in the CIN II or III state, regress to the normal state, or progress towards the persistent CIN II or III state. From there, patients may remain in the persistent CIN II or III state, regress to the normal state, or progress towards the cervical cancer state. When individuals reach the cervical cancer state, we assume no regression is possible; that is, they can only progress to a cured cancer state when alive at 5 years after diagnosis or to the cervical cancer death state. In this model, a female in any state can die because of other causes.

Screening strategies

This study was designed to compare a no-screening strategy with nine different screening strategies, which varied using three different screening algorithms – Pap smear alone, HPV DNA testing followed by Pap smear triage, and HPV DNA testing combined with Pap smear, with three screening intervals annually, every 3 years, and every 5 years. We assume the ceiling age for screening is 69 years.

Table 1 lists the primary screening and triage tool, screening ages, screening interval, and coverage for each strategy. We assume a 30% coverage rate for annual screening, based on the reported 28.4% of females aged 30–69 years who had a Pap smear in 2007. Similarly, 3-year (60%) and 5-year coverage rates (75%) were assumed as the reported percentages of 52.3% and 64.9% of those who underwent at least one Pap smear during a 3- or 5-year period, respectively.

When a female is invited to undergo cervical cancer screening, she is stratified into the never-screened or regularly screened categories (Figure 1). According to research by Chen et al. (2009), after implementing the screening program in 1995, roughly 75% eligible females in Taiwan participated in the program at least once by 2007. We infer that the percentage of those never screened was 25%. Considering the uncertainty, 12% and 30% as low and high estimate values were changed during sensitivity analysis.

In the regular screening strata, a female may or may not be willing to participate in an appropriate year. If a female chooses to undergo screening, the following three combinations of screening tools were evaluated: (1) Pap smear as the primary screening test followed by colposcopy-guided biopsy for positive Pap smear results (i.e., Pap); (2) HPV DNA testing as the primary screening test, using a Pap smear as a triage strategy for those who test positive for high-risk HPV types in HPV DNA testing (i.e., HPV-Pap); and (3) HPV DNA testing as the primary screening test, using a Pap smear as a follow-up screening strategy for those who have positive Pap smear results or test positive for high-risk HPV types (i.e., combination).

Experts and existing guidelines were consulted before making the following assumptions for management of females with different screening results: (1) women with negative primary screening results are asked to undergo regular screening; (2) when a woman had a positive final screening result, she is urged to undergo a colposcopy-guided biopsy. All women with a confirmed histology of CIN I, CIN II or III and cancer are assumed to be treated with the therapy recommended by the Taiwan Cooperative Oncology Group (Taiwan Cooperative Oncology Group, 2007). These patients are assumed treated immediately after disease confirmation. When treatment was
completed, annual Pap smear screening followed; (3) in the HPV-Pap and combination strategies, those negative after follow-up screenings are suggested to undergo annual Pap smear screening for the rest of their lifetime.

We further assume that compliance with follow-up and treatment is 100% in the model.

Model parameters

Table 2 summarises the probabilities, costs, and data sources used in the base-case analysis.

Parameters of the natural history model Parameters of HPV infection rates and disease transitions were obtained from the study by Debicki et al (2008). They estimated disease parameters by reviewing published reports of Taiwanese screening coverage and incidence, and further calibrated disease parameters to fit cervical endpoints. The succinct model, which adopted fewer complex processes and a short cycle length of 1 year, was used in this study.

Survival rate and death probability The annual probabilities of dying from cervical cancer for patients were obtained from survival rates published by the Taiwan Cancer Registry (2007). The 1-, 2-, 3-, 4-, and 5-year survival for patients with invasive cervical cancer (all stages) in Taiwan were 90.4, 83.2, 79.4, 76.7, and 74.8%, respectively.

Age-specific other-cause mortality was obtained from the 2007 Life Table for Taiwan's female population (Department of Statistics, 2008). For example, the probability of dying, which increases with age, was 0.00055 for those aged 30 and 1 for those aged 85.

Screening test characteristics Test sensitivity was defined as a positive screening result for patients with CIN I or worse in this model. Test specificity was defined as a negative result for females in the normal state. Screening test characteristics used were obtained from and Mayrand et al (2007). Mayrand et al conducted a randomised trial comparing the sensitivity and specificity of the HPV DNA testing and Pap smear for females aged 30–69 years in Canada (n = 10 154). This study used Pap smear sensitivity for CIN II or III of 55.4% (95% CI = 33.6–77.2%), and a specificity of 96.8% (95% CI = 96.3–97.3%). Arbyn et al conducted meta-analyses of clinical applications of the HPV DNA testing. Their analytical results indicated that sensitivity of the HPV DNA testing (89.5%; 85.1–93.1%) or the combination of the HPV DNA testing with Pap smear (99.2%; 97.4–100.0%) are higher than Pap smear alone in other studies for detecting CIN II cases or worse. The specificity was 87.5% (95% CI = 85.0–89.9%) for

Table 1 Cervical cancer primary screening and follow-up tool, screening ages, screening interval, and coverage for each strategy

| Screening strategy* | Primary screening | Follow-up screeninga | Screening ages, year | Screening interval, year | Coverage, %b |
|---------------------|-------------------|----------------------|---------------------|--------------------------|-------------|
| Pap, 1-y            | Pap smear         | —                    | 30–69               | 1 year                   | 30.0 (27.4–50.0) |
| Pap, 3-y            | Pap smear         | —                    | —                   | 3 year                   | 60.0 (52.4–65.0) |
| Pap, 5-y            | Pap smear         | —                    | —                   | 5 year                   | 75.0 (70.0–75.0) |
| HPV-Pap, 1-y        | HPV DNA testing   | Pap smear            | 1 year              | 1 year                   | 30.0 (27.4–50.0) |
| HPV-Pap, 3-y        | HPV DNA testing   | Pap smear            | 3 year              | 3 year                   | 60.0 (52.4–65.0) |
| HPV-Pap, 5-y        | HPV DNA testing   | Pap smear            | 5 year              | 5 year                   | 75.0 (70.0–75.0) |
| Combination, 1-y    | Combine HPV DNA testing with Pap smear | Repeat Pap smear | 1 year | 1 year | 30.0 (27.4–50.0) |
| Combination, 3-y    | Combine HPV DNA testing with Pap smear | Repeat Pap smear | 3 year | 3 year | 60.0 (52.4–65.0) |
| Combination, 5-y    | Combine HPV DNA testing with Pap smear | Repeat Pap smear | 5 year | 5 year | 75.0 (70.0–75.0) |

Abbreviation: HPV = human papillomavirus. *Pap’ refers to Pap smear as primary screening test follows by colposcopy-guided biopsy for positive Pap smear results. ‘HPV-Pap’ refers to HPV DNA testing as primary screening test, using Pap smear as a triage strategy for those who test positive for high-risk HPV types in HPV DNA testing results. ‘Combination’ refers to HPV DNA testing in combination with Pap smear as primary screening test, using Pap smear as a follow-up screening strategy for those who have Pap smear results or test positive for high-risk HPV types. ‘1-y’, ‘3-y’, and ‘5-y’ refer to a 1-year, 3-year, and 5-year screening intervals for women 30 – 69 years of age, respectively. aFollow-up of positive primary screening results. ‘1-y’, ‘3-y’, and ‘5-y’ refer to a 1-year, 3-year, and 5-year screening intervals for women 30 – 69 years of age, respectively. bScreening ages, screening interval, and coverage results are estimated from published reports of Taiwanese screening coverage and incidence. The specificity was 87.5% (95% CI = 85.0–89.9%) for

Figure 1 Screening decision tree showing different screening tests at three screening intervals and follow-up management.
HPV DNA testing and 87.3% (95% CI = 87.3–90.4%) for the combination test.

Utility weight data The health utility data for the base case and ranges were adopted from a CEA evaluating HPV vaccination programs in Taiwan (Suárez et al., 2008), which was compiled using health utility data collected in the USA (Insigna et al., 2007).

Costs data From a perspective of Department of Health, only costs associated with direct medical costs were utilised. Furthermore, this study included only the direct medical costs associated with use of health-care services covered by the NHI program.

The category for costs associated with cervical cancer consists of costs of screening tests, costs of diagnosis, costs of treatment for CIN I, CIN II or III, and cancer treatment costs.

Screening costs Pap smear screening as a procedure for cervical cancer prevention includes: (1) Pap smear sampling, (2) pelvic examination, and (3) Pap smear cytological examination.

| Table 2 Model parameters of the decision analytic model for cervical cancer |
|-----------------------------------------------|
| Model parameter | Base case | Range | Reference |
| Natural history | | | |
| Normal to HPV | 0.06 | 0–0.17 | Debicki et al. (2008); |
| HPV to CIN I | 0.049 | 0.028–0.07 | Rogozza et al. (2008); |
| CIN I to II/III | 0.091 | 0.08–0.30 | |
| CIN II/III to persistent CIN II/III | 0.114 | 0–0.114 | Suárez et al. (2008) |
| Persistent CIN II/III to cancer | 0.05 | 0–0.10 | |
| HPV regression | 0.516 | 0.435–0.67 | |
| CIN I regression | 0.449 | 0.31–0.54 | |
| CIN II/III regression | 0.227 | 0.04–0.227 | |
| 5-year survival rate from cervical cancer, % | | | Taiwan Cancer Registry (2007) |
| 1-year | 90.4 | 85.4–95.4 | |
| 2-year | 83.2 | 78.2–88.2 | |
| 3-year | 79.4 | 74.4–84.4 | |
| 4-year | 76.7 | 71.7–81.7 | |
| 5-year | 74.8 | 69.8–79.8 | |
| Test characteristics, % | | | |
| Sensitivity of Pap smear | 55.4 | 33.6–77.2 | Mayrand et al. (2007) |
| Sensitivity of HPV DNA testing | 89.5 | 85.1–93.1 | Arbyn et al. (2006) |
| Sensitivity of Pap smear and HPV DNA testing | 99.2 | 79.4–100 | Arbyn et al. (2006) |
| Specificity of Pap smear | 96.8 | 96.3–97.3 | Mayrand et al. (2007) |
| Specificity of HPV DNA testing | 97.5 | 85.0–89.9 | Arbyn et al. (2006) |
| Specificity of Pap smear and HPV DNA testing | 87.3 | 87.3–90.4 | Arbyn et al. (2006) |
| Utility value (6-month) | | | Suárez et al. (2008) |
| Normal population | 1.00 | 1.00 | |
| HPV | 1.00 | 0.99–1.00 | |
| CIN I | 0.96 | 0.92–0.99 | |
| CIN II/III | 0.96 | 0.92–0.99 | |
| Treated cancer | 0.73 | 0.58–0.87 | |
| Cured/follow-up cancer | 0.94 | 0.62–0.97 | |
| Direct medical costs, NT$ | | | |
| Screening test, NT$ | | | |
| Pap smear* | 430.0 | BNHI (2009) |
| HPV DNA testing | 600.0 | Market price |
| HPV DNA testing and Pap smear | 1030.0 | |
| Diagnosis costs, NT$ | | | |
| Repeat Pap smear† | 440.0 | BNHI (2009) |
| Colposcopy (with biopsy) | 2183.0 | Debicki et al. (2008) |
| Treatment costs, NT$ | | | |
| CIN I | 2347.0 | Tang et al. (2010) |
| CIN II/III | 6956.0 | |
| 1st year of cervical cancer | 232 389.0 | |
| 2nd year of cervical cancer | 123 250.0 | |
| 3rd year of cervical cancer | 167 009.0 | |
| 4th year of cervical cancer | 95 645.0 | |
| 5th year of cervical cancer | 113 627.0 | |

Abbreviations: CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; NHI = National Health Insurance. *Sensitivity was defined as a screening positive result for patients with CIN I or worse in this model. Specificity was defined as a negative result for women in normal state. †Range between −50% and +50% of the base-case value unless otherwise indicated. ‡Direct medical costs were the costs associated with the use of health-care services covered by the NHI program. §Pap smear screening procedures were (1) Pap smear sampling, (2) a pelvic examination, and (3) Pap smear cytological examination. Health-care providers are reimbursed NT$430 by the NHI system for these services. The procedures for a repeated Pap smear are (1) vaginal irrigation, (2) a pelvic examination, (3) obtaining a Pap smear sample, and (4) a Pap smear cytological examination. Health-care providers are reimbursed NT$440 by the NHI system for these services.
Health-care providers are reimbursed NT$430 by the NHI system for these services (Bureau of National Health Insurance, 2009). Additionally, the average price of the HPV DNA testing is assumed to be NT$600.

**Diagnostic costs** For the HPV-Pap and combination strategies, patients who had a positive primary screening test underwent another Pap smear test. The procedures for a repeated Pap smear are (1) vaginal irrigation, (2) pelvic examination, (3) obtaining Pap smear sample, and (4) Pap smear cytological examination. Health-care providers are reimbursed NT$440 by the NHI system for these services (Bureau of National Health Insurance, 2009). Those who had a positive primary screening test with the Pap strategy, or had a positive final screening result with the HPV-Pap or combination strategy, or have been with cervical cancer or precancerous lesion, are referred to take a colposcopy-guided biopsy. Diagnostic cost of the colposcopy-guided biopsy was NT$2183 (Debicki et al., 2008).

**Treatment costs** Direct medical costs for precancerous lesions and cervical cancer treatments in Taiwan were obtained from the study by Tang et al. (2010). All costs are reported in New Taiwan Dollars (in this study, US$1.00 = NT$33.032).

**Sensitivity analysis** Considering uncertainty is crucial in a decision analytical study. To better understand the impact on the results for different levels of participation, along with the purpose to present the validity of the model results, a scenario sensitivity analysis was performed by approximating the highest coverage rate at 100% for all screening intervals. Probabilistic sensitivity analyses (PSAs) were conducted to assess parameter uncertainty. The ranges of parameters were mostly from published studies (Table 2). A 50% increase or decrease in the base-case value for costs data were changed during sensitivity analysis.

Probability distributions were defined for the following six sets of model parameters: (1) screening rate; (2) disease transition probabilities in the natural history model; (3) survival rate for cervical cancer; (4) test characteristics; (5) utility; and, (6) costs. A beta distribution was fitted for screening rate, the natural history model, survival rate for cervical cancer, test characteristics, and utility, those parameters were between 0 and 1. A gamma distribution can be used to represent uncertainty in cost data, which was constrained to be non-negative and characterised in the interval of 0 to positive infinity (Briggs et al., 2007).

The PSA results in this model were analysed using cost-effectiveness acceptability frontier (CEAF) constructed from cost-effectiveness acceptability curves (CEACs) for the different strategies. The CEACs were calculated from net monetary benefit over a range of willingness-to-pay (WTP) thresholds for each strategy, and produced by plotting the probability of being cost-effective for a strategy under different WTP thresholds (Barton et al., 2008). To further determine the uncertainty associated with a priori intervention over all WTP thresholds for each strategy (Fenwick et al., 2001), this study produced a CEAF by identifying the probability of the optimal strategy in each of 1000 iterations based on the strategy with the highest expected net benefits at different WTP thresholds (Barton et al., 2008).

**RESULTS**

**Base-case analysis** Table 3 presents the lifetime effectiveness and costs for a hypothetical cohort of 30-year-old females for all nine screening strategies. Predicted effectiveness outcomes were lifetime incidence and mortality for cervical cancer, total life expectancy, and total QALYs; additionally, total lifetime costs, and ICERs calculated by comparing different bases (i.e., the no-screening strategy, Pap annual strategy, and next-best strategy) are presented.

**Reduction in lifetime risk** Compared with the no-screening strategy, all nine screening strategies were more effective (Table 3). The estimated reduction in lifetime incidence and related mortality for cervical cancer when screened at 30 years of age varies at 35.8–71.1%, depending on screening tests, screening intervals, and screening strategies. The HPV-Pap and combination strategies at annual, 3-, or 5-year intervals prevented more cases than the Pap strategy at annual, 3-, or 5-year screening intervals. The model estimated cervical cancer cases at 87.6–118.2 per 100,000 women and a related mortality of 25.6–34.8 per 100,000 patients with the Pap strategy; 54.6–70.0 cases and 16.3–20.7 deaths for the HPV-Pap strategy; and 53.2–65.2 cases and 15.9–19.3 deaths with the combination strategy (Table 3).

**Cost-effectiveness analysis** Figure 2 presents the cost-effectiveness results that indicate all nine screening strategies
generated greater effectiveness (i.e., total QALYs) and total costs than the no-screening strategy from the perspective of the Department of Health. Using three times Taiwan’s per capita GDP as the cost-effectiveness threshold, all these strategies were cost-effective. However, when each strategy compared with the next most-effective non-dominated strategy, an annual Pap, combination every 5 years and every 3 years were extended-dominated. Pap every 5 years and every 3 years, HPV-Pap every 5 years and every 3 years had ICERs of NT$66 000, NT$89 000, NT$1 323 000, NT$1 358 000 per QALY gained, respectively. These strategies were cost-effective at three times per capita GDP threshold.

If the current screening strategy, an annual Pap, is used for comparison, HPV-Pap every 3 years and every 5 years cost NT$1 303 000 and NT$1 247 000 per QALY gained, respectively. These strategies are < NT$1 620 000/QALY. However, extending screening intervals for Pap annually to every 3 or 5 years was less costly but also less effective. Changing Pap annually to every 3 or 5 years save NT$1 197 to NT$1 890 while loss 0.33–0.62 of discounted quality-adjusted life days per woman (see Table 3 and Figure 2).

### Sensitivity analysis

The coverage rate changes into 100% for all screening intervals in the scenario sensitivity analysis. Results show that screening strategies on the sensitivity analysis efficiency frontier in this analysis are Pap every 5 years and 3 years, HPV-Pap every 5 years, every 3 years and annually, and combination annually (Figure 3). The ranking, and the magnitude of the discounted QALYs and costs, of the alternatives are as expected (i.e., programs with the annual screening are the most efficacious and the most costly), suggesting the validity of this model.

The PSA results are presented in a CEAF. The CEAF was plotted by presenting the optimal strategy under different WTP thresholds (Figure 4). When three times GDP per capita is used as the decision threshold, the annual Pap strategy (< NT$207 000), the annual HPV-Pap strategy (NT$207 000–351 000), the Pap strategy every 5 years (NT$351 000–594 000), the HPV-Pap strategy every 5 years (NT$594 000–1 413 000), and the HPV-Pap strategy every 3 years (> NT$1 413 000) achieved the highest expected net benefits.

### DISCUSSION

Screening has proven cost-effective in preventing cervical cancer according to many studies conducted in different countries (Mandelblatt et al., 2002a, b; Mittendorf et al., 2003; Goldie et al., 2004, 2005; Kim et al., 2004, 2005; Holmes et al., 2005; Siebert et al., 2006; Anderson et al., 2008; Andres-Gamboa et al., 2008; Bistoletti et al., 2008; Muhlberger et al., 2008; Chuck, 2009; Vijayaraghavan et al., 2009); the model results in this study demonstrate the cost-effectiveness of screening compared with that of a no-screening strategy, regardless of which screening tool or interval is used. Compared with the annual Pap strategy, the HPV-Pap strategy at 3- or 5-year intervals are cost-effective. Annual HPV-Pap strategy, combination strategy annually or at 3- or 5-year intervals generated the greatest effectiveness, while cost a substantial amount of total costs; thus, the annual HPV-Pap and the combination strategies are not cost-effective. For a nation with a publicly financed health-care system, such as Taiwan, this study shows that extending cervical cancer screening interval from Pap annually to HPV-Pap strategy every 3 or 5 years costs NT$1 303 000 or NT$1 247 000 per QALY gained, respectively.

Compared with the no-screening strategy, Pap annually and Pap every 3 and 5 years reduced the incidence of cervical cancer in a lifetime by 52.4, 44.1, and 35.8% under the coverage assumptions in this model. Arbyn et al. (2006) and Mayrand et al. (2007) indicated that the HPV DNA testing has greater sensitivity and is more accurate than Pap smear for detecting HSILs. As expected, analytical results demonstrate that the HPV-Pap or combination strategy annually or at 3- or 5-year screening intervals prevented more cases than the Pap strategy annually or at 3- or 5-year screening intervals. The reductions in lifetime incidence of cervical cancer with the HPV-Pap strategy annually or at 3- or 5-year screening intervals were 70.3, 67.4, and 62.0%; the values for the combination strategy were 71.1% (annually), 69.0% (every 3 years), and 64.6% (every 5 years). Two studies undertaken in the United States reported a decline in lifetime incidence of cervical cancer of 70–87% (Mandelblatt et al., 2002b) and 81–90% (Goldie et al., 2004) for Pap smear alone with different screening intervals. The HPV DNA testing with a Pap smear in a cervical cancer screening program decreased risk by 78–93% (Mandelblatt et al., 2006; Anderson et al., 2008; Bistoletti et al., 2008; Chuck, 2009; Vijayaraghavan et al., 2009).
2002b) and 90–93% (Goldie et al., 2004). This study identified an increasing trend of a reduction in the incidence of cervical cancer that is consistent with findings obtained with other models comparing the HPV DNA testing with Pap smear alone.

Several studies demonstrated that using the HPV DNA testing as primary screening or combined with Pap smear with a screening interval of every 2, 3, or 5 years was more cost-effective than Pap smear alone (Mandelblatt et al., 2002b; Mittendorf et al., 2003; Goldie et al., 2004; Kim et al., 2005; Bistoletti et al., 2008; Chuck, 2009). Analytical results in this study demonstrate that the HPV-Pap strategy at 3- or 5-year intervals was cost-effective; this finding is generally consistent with those studies. However, the results of this model demonstrate that the combination strategy, regardless of screening intervals, were not cost-effective compared with current cervical cancer screening program (Pap annually). Three important factors were considered in this study. First, the combination strategy annually and at 3- and 5-year intervals were more effective (i.e., total QALYs) than Pap annually. The combination annually strategy saves 0.69 days of discounted QALY per woman compared with Pap annually. Whereas total costs of the combination strategy is more than 1.4-fold (combination every 5 years) to 2.0-fold (combination annually) that of the annual Pap strategy (NT$4242) (Table 3). Thus, extending the cervical cancer screening interval from Pap annually to HPV-Pap strategy every 3 or 5 years can be considered.

Second, differences in cost structures may account the difference between cost-effectiveness results in this study and those obtained by other studies using the HPV DNA testing as primary screening or combined with Pap smear for cervical cancer screening. The unit cost of the HPV DNA testing is 40% more than that of a Pap smear in Taiwan. Conversely, the unit cost of the HPV DNA testing is roughly identical to that of Pap smear in many European countries and in the United States (Mandelblatt et al., 2002b; Kim et al., 2004, 2005; Bistoletti et al., 2008). In comparison, the...
screening cost of the HPV-Pap and combination strategies are higher in Taiwan than in other countries.

Third, using the HPV DNA testing increased disease cases by detecting more precancerous lesions than Pap smear alone (Naular, et al, 2009). The costs of treatment with the HPV-Pap or combination strategy may be lower than Pap smear alone theoretically. In fact, the costs of treatments for precancerous lesions and cervical cancer in Taiwan are lower than those in many countries (Goldie et al, 2004; Kim et al, 2004, 2005; Tang et al, 2010). For instance, treatment cost was roughly NT$9656 for CIN II or III patients. These figures are more than three-fold in the UK (US$676, about NT$22 463) and seven-fold in the United States (US$2833, about NT$93863). Moreover, overall invasive cervical cancer treatment costs are 1.6-fold higher in the Netherlands (US$17 603, about NT$583223) to 2.8-fold higher in the UK (US$31 494, about NT$1043 443) than in Taiwan (NT$375 322).

The difference in treatment cost between the HPV-Pap or combination strategy and Pap smear alone is less in Taiwan than that in other countries. Consequently, using the HPV DNA testing has the potential to improve health effectiveness at a reasonable cost compared with the Pap smear in European countries and in the United States is not surprising. Early detection of precancerous lesions may not reduce treatment costs largely; thus, it may have difficulty being cost-effective when treatment costs are generally lower in Taiwan than in other countries.

Analytical results demonstrated that extending screening intervals from Pap annually to every 3 or 5 years would save costs but be less effective; this finding is generally consistent with those in studies by Anderson et al (2008) and Siebert et al (2006). The population of women aged >30 years, that is, those targeted for cervical cancer screening, was estimated at approximately 7 million in Taiwan in 2008 (Directorate-General of Budget, Accounting and Statistics, 2009b). However, the budget for the screening program (free annual Pap smear—approximately NT$430 for one Pap smear) from the Bureau of Health Promotion, Department of Health, was only NT$860 million annually (Liberty Times, 2009). Although this figure seems quite small, it hardly meets the expenses under low participation. As a result of the limited resources available for cervical cancer screening programs, implementing an annual screening program is barely affordable. The cost-effectiveness results obtained by this study suggest that HPV-Pap every 3 or 5 years represent the use of resources considering improve participation rate and extending screening intervals.

Some studies have explored factors associated with low participation for the cervical cancer screening program in Taiwan (Lee et al, 1997; Lin et al, 2003, 2007). These factors may be summarised as Taiwanese women having a more lax attitude toward cervical cancer screening programs, perhaps because of societal values or those in traditional culture. This is also at play in the difficulty policy-makers have faced during the last decade in determining how to improve coverage for Pap smear screening. One alternative to screening may be self-sampling, which may make cervical cancer screening more accessible to women not participating in the current screening program or those rarely contacting health-care centers, offering an important method for increasing cervical cancer screening coverage (Sellors et al, 2000; Wright et al, 2000; Agorastos et al, 2005; De Alba et al, 2008).

In conclusion, this study demonstrates that, compared with a no-screening or an annual Pap strategy, using the HPV DNA testing in the cervical screening program in Taiwan is cost-effective. This study also identified as cost-effective for extending the cervical cancer screening interval from Pap annually to HPV-Pap strategy every 3 or 5 years had ICERs of NT$1 303 000 or NT$1 247 000 per QALY gained, respectively. Considering the potential economic advantages, HPV-Pap strategy every 5 years would seem to be more attractive, especially in Taiwan, a country with a publicly financed health-care system.

ACKNOWLEDGEMENTS

We thank the Bureau of Health Promotion, Department of Health of the Republic of China (Taiwan), for financial support of this research. The Taiwan Cancer Registry taskforce, as well as the Taiwan Cervical Cancer Screening Registration taskforce, is appreciated for their technical assistance in making data available. Ted Knoy is appreciated for his editorial assistance.

REFERENCES

Agorastos T, Dinas K, Lloveras B, Font R, Kornegay JR, Bontis J, De Sanjose S (2005) Self-sampling vs physician-sampling for human papillomavirus testing. Int J STD AIDS 16: 727–729

Anderson R, Haas M, Shanahan M (2008) The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals over a different age range? Aust N Z J Public Health 32: 43–52

British Journal of Cancer (2010) 103(12), 1773 – 1782

© 2010 Cancer Research UK
Clinical Studies

Cea of HPV DNA testing and Pap smear in Taiwan

I-Hi Chow et al

© 2010 Cancer Research UK

British Journal of Cancer (2010) 103(12), 1773 – 1782

Barton GR, Briggs AH, Fenwick EAL (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 11: 886 – 897

Bistoletti P, Sennfalt K, Dillner J (2008) Cost-effectiveness of primary cytology and HPV DNA cervical screening. Int J Cancer 122: 372 – 376

Briggs A, Claxton K, Sculpher M (2007) Decision Modelling for Health Economic Evaluation. Oxford University Press Inc.: New York

Bureau of Health Promotion (2007) Pap Smear Screening Registry System Annual Report 2006. Report no. 1992–4695. Department of Health, Executive Yuan: Republic of China (Taiwan)

Bureau of National Health Insurance (2009) The Fee Schedule for Medical Services of National Health Insurance. Department of Health, Executive Yuan: Republic of China (Taiwan). http://www.nhi.gov.tw/inquire/query2.asp?menu=1&menu_id=88&WD_ID=94. Updated on 11 September 2009 (in Chinese)

Chen YY, You SL, Chen CA, Shih LY, Koong SL, Chao KY, Hsiao ML, Hsieh CY, Chen CJ (2009) Effectiveness of national cervical cancer screening programme in Taiwan: 12-year experiences. Br J Cancer 101: 174 – 177

Chuck A (2009) Cost-effectiveness of 21 alternative cervical screening strategies. Value Health 2010; 13: 169 – 179

De Alba I, Anton-Culver H, Hubbell FA, Ziogas A, Hess JR, Bracho A, Arias C, Manetta A (2008) Self-sampling for human papillomavirus in a community setting: feasibility in Hispanic women. Cancer Epidemiol Preven 17: 2124 – 2168

Debicki D, Ferko N, Demartane N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou C-Y, Standert B, Annemans L (2008) Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 26: F16 – F28

Department of Statistics (2008) Life Tables for Republic of China, Abridged life table in Taiwan-Fuchien-Area Female-2007. Ministry of the Interior, Executive Yuan: Republic of China (Taiwan), http://www.moi.gov.tw/stat/life.axs. Updated on 21 November 2008

Dillner J, Reboli M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Nauleur P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Itfner T (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337: a1754

Directorate-General of Budget, Accounting and Statistics (2009a) Press Release of National Income and Domestic Economic Outlook. Executive Yuan: Republic of China (Taiwan), http://www.dgbas.gov.tw/public/data/dgbas05/bst/bstninews/9905.pdf. Updated on 20 July 2009 (in Chinese)

Directorate-General of Budget, Accounting and Statistics (2009b) Resident Population by Single Year of Age in Taiwan-Fuchien Area (End of 1974 – 2008). Executive Yuan, Republic of China (Taiwan), http://sosw.moi.gov.tw/stat/month/ml-06.xls. Updated on 20 July 2009 (in Chinese)

Eicher HG, Hong SX, Gerth WC, Mavros P, Jonson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how do the cost-effectiveness thresholds expected to emerge? Value Health 7: 518 – 528

Fenwick E, Claxton K, Sculpher M (2001) Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10: 779 – 787

Goldie SJ, Gafflikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC (2005) Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353: 2158 – 2168

Goldie SJ, Kim JJ, Wright TC (2004) Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France, and Italy. J Natl Cancer Inst 97: 888 – 895

Hsiao SL, Yen AM, Chen TH (2006) Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen 13(Suppl 1): S44 – S47

Lee TF, Kuo HS, Chen HC, Chen TS, Chou P (1997) Factors related to acceptance of Pap test by women in Kinmen. Chinese J Public Health 16: 198 – 210

Liberty Times (2009) http://www.libertytimes.com.tw/2006/new/dec/12/today-life11.htm. Updated on 21 August 2009 (in Chinese)

Lin HH, Chen SH, Jeng SY, Chen HM (2007) A project to improve the screening rate of Pap smear for cervical cancer. J Nurs 54: 62 – 69

Lin HS, Wang LH, Liu S, Kang CC (2003) Factors associated with papanicolaou smear practice in women in the Pingtung area. Taiwan J Public Health 22: 127 – 133

Mandelblatt JS, Lawrence WF, Gafflikin L, Limpahayom KK, Lumbiganon P, Warakamin S, King Y, Bi R, Ringers P, Blumenthal PD (2002a) Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst 94: 1469 – 1483

Mandelblatt JS, Lawrence WF, Wornack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K (2002b) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287: 2372 – 2381

Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratsam S, Coutelle F, Franco EL (2007) Human papillomavirus DNA vs Papanicolaou screening tests for cervical cancer. N Engl J Med 357: 1579 – 1588

Mittendorf T, Petry KU, Itfner T, Greiner W, von der Schuelenburg JM (2003) Economic evaluation of human papillomavirus screening in Germany. Eur J Health Econ 4: 209 – 215

Muhlberger N, Sroczyinski G, Esteban E, Mittendorf T, Miksad RA, Siebert U (2008) Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care 24: 184 – 192

Nauler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J (2009) Efficacy of HPV DNA testing with cytology triage and/ or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101: 88 – 99

Patrick J (2000) Cervical cancer screening in England. Eur J Cancer 36: 2205 – 2208

Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhoff J, Wang K-L, Downs L, Smith JS, Franco EL (2008) Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 26: F46 – F58

Schaffer P, Sancho-Garnier H, Fender M, Dellenbach P, Garbillet JP, Morello, Gauthier GP, Morello A (2000) Cervical cancer screening in France. Eur J Cancer 36: 2215 – 2220

Sellors JW, Lorincz AT, Mahony JB, Mielczynska I, Lytwyn A, Roth P, Howard M, Chong S, Daya D, Chapman W, Clernesky M (2000) Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. Can Med Assoc J 163: 513 – 518

Siebert U, Sroczyński G, Hielsmann P, Engel J, Stabenow B, Stegmaier C, Voigt K, Gibis B, Holzel D, Goldie SJ (2006) The German Cervical Screening Model: development and validation of a decision-analytic model for cervical screening in Germany. Eur J Public Health 16: 185 – 192

Suarez E, Smith JS, Bosch FX, Nieminen P, Chen C-J, Torviren S, Demartane N, Standert B (2008) Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 26: F29 – F45

Taiwan Cancer Registry (2007) 7-year cervical cancer survival rate, by FIGO stage. Bureau of Health Promotion, Department of Health, Executive Yuan: Republic of China (Taiwan), http://tcr.cph.ntu.edu.tw/upload_images/%20Cervix%20Cancer_FIGO.pdf. Updated on 20 July 2009 (in Chinese)

Taiwan Cooperative Oncology Group (2007) Clinical Practice Guidelines for Gynecologic Oncology. National Institute of Cancer Research, National Health Research Institutes, Republic of China (Taiwan): Miaoli County Tang CH, Pwu RF, Tsai IC, Wang HI, You SL, Chen CA, Scuffham PA, Hsieh CY, Chou CY, Lin SR, Chen YD, Chen CJ (2010) Costs of cervical...
cancer and precancerous lesions treatment in a publicly financed health care system. Arch Gynecol Obstet 281: 683 – 695
TreeAge Software INC (2009) TreeAge Pro User’s Manual. TreeAge Software INC.: Williamstown, MA
Van Ballegooijen M, Hermens R (2000) Cervical cancer screening in the Netherlands. Eur J Cancer 36: 2244 – 2246

Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santos C (2009) Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol 112: 377 – 383
Wright TC, Denny L, Kuhn L, Pollack A, Lorincz A (2000) HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283: 81 – 86